DR. MICHAEL S. GERMAN, M.D.
Osteopathic Medicine at Parnassus Ave, San Francisco, CA

6436667, Aug 20, 2002

Jan 20, 1998

09/009816

Michael S. German - San Francisco CA
M. Alan Permutt - St. Louis MO
Hiroshi Inoue - Yamaguchi, JP

The Regents of the University of California - Oakland CA
Washington University - St. Louis MO

C07H 2104

435 691, 435325, 43525233, 4353201, 536 235, 536 2431, 530350

The present invention features a human Nkx-6. 1 polypeptide and nucleotide sequences encoding Nkx-6. 1 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Nkx-6. 1 polypeptide. The present invention also relates to antibodies that bind specifically to a human Nkx-6. 1 polypeptide, and methods for producing human Nkx-6. 1 polypeptides.

6703220, Mar 9, 2004

Mar 24, 2000

09/535145

Michael S. German - San Francisco CA
Joseph Lin - San Francisco CA

The Regents of the University of California - Oakland CA

C12N 1512

435 691, 435325, 4353201, 4352523, 536 235, 536 231

The present invention features a human neurogenin3 (Ngn3) polypeptide and nucleotide sequences encoding Ngn3 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features isolated nucleic acid sequence comprising an Ngn3 promoter, as well as a polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Ngn3 polypeptide. The present invention also relates to antibodies that bind specifically to a human Ngn3 polypeptide, methods for producing human Ngn3 polypeptides, methods for identifying -cell precursor cells expressing Ngn3, methods for using the Ngn3 gene and the Ngn3 polypeptide to alter cellular differentiation in culture or in vivo to produce new -cells to treat patients with diabetes mellitus, and identification of individuals at risk for diabetes by detecting alteration in Ngn3 coding and regulatory sequences and Ngn3 expression levels.

6831070, Dec 14, 2004

Mar 16, 2001

09/811323

Michael German - San Francisco CA
Ira D. Goldfine - Kentfield CA
Stephen S. Rothman - Berkeley CA

Regents of the University of California - Oakland CA

A61K 4800

514 44, 424482, 424486, 4353201

The present invention provides methods of delivering a secreted protein into the bloodstream of a mammal. A nucleic acid molecule encoding the protein is introduced into the gastrointestinal tract of the mammal, and the nucleic acid molecule enters an intestinal epithelial cell, where the protein is produced and secreted into the bloodstream of the mammal.

6225290, May 1, 2001

Sep 19, 1996

8/717084

Michael German - San Francisco CA
Ira D. Goldfine - Kentfield CA
Stephen S. Rothman - Berkeley CA

The Regents of the University of California - Oakland CA

A61K 4800, C12N 1500

514 44

Intestinal epithelial cells of a mammalian subject are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect. Intestinal cell transformation is accomplished by administration of a formulation composed primarily of naked DNA, and is preferably administered orally. Oral or other intragastrointestinal routes of administration provide a simple method of administration, while the use of naked nucleic acid avoids the complications associated with use of viral vectors to accomplish gene therapy. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed intestinal epithelial cells provide short or long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.

6239258, May 29, 2001

Jan 20, 1998

9/008892

Michael S. German - San Francisco CA
Graeme I. Bell - Chicago IL
Hiroto Furuta - Wakayama, JP
Lori Sussel - San Francisco CA

The Regents of the University of California - Oakland CA
Arch Development Corp. - Chicago IL

A61K 3816, C07H 2104, C07H 2102, C12P 2106, C12N 1500

530358

The present invention features a human Nkx-2. 2 polypeptide and nucleotide sequences encoding Nkx-2. 2 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Nkx-2. 2 polypeptide. The present invention also relates to antibodies that bind specifically to a human Nkx-2. 2 polypeptide, and methods for producing human Nkx-2. 2 polypeptides.

5837693, Nov 17, 1998

Mar 24, 1995

8/410660

Michael German - San Francisco CA
Ira D. Goldfine - Kentfield CA
Stephen S. Rothman - Berkeley CA

The Regents of the University of California - Oakland CA

A01N 4304

514 44

Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.

6004944, Dec 21, 1999

Oct 2, 1997

8/942939

Stephen S. Rothman - Berkeley CA
Ira D. Goldfine - Kentfield CA
Michael S. German - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 4800, C12N 1500

514 44

Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.

2005002, Feb 3, 2005

Aug 3, 2004

10/911082

Michael German - San Francisco CA, US
Ira Goldfine - Kentfield CA, US
Stephen Rothman - Berkeley CA, US

Regents of the University of California - Oakland CA

A61K048/00, C12N015/85

514044000, 435455000

Intestinal epithelial cells of a mammalian subject are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect. Intestinal cell transformation is accomplished by administration of a formulation containing DNA and is preferably administered orally. Oral or other intragastrointestinal routes of administration provide a simple method of administration. The expressed protein is secreted directly into the gastrointestinal tract and/or bloodstream to obtain therapeutic blood levels of the protein, thereby treating the patient in need of the protein. The delivery system of the invention provides short or long term delivery of therapeutic gene products.